Vital Therapies Announces Upcoming First Quarter Financial Results Conference Call with Webcast and Upcoming Conference Presentation
28. April 2016 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, April 28, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
08. März 2016 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, March 08, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Upcoming Fourth Quarter and Full Year 2015 Financial Results Conference Call With Webcast
24. Februar 2016 08:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, will...
Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 Phase 3 Trial
19. November 2015 08:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure,...
Vital Therapies Announces Late Breaker and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Disease
18. November 2015 08:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure,...
Vital Therapies Announces Third Quarter 2015 Financial Results and Provides Corporate Update
05. November 2015 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares
28. Oktober 2015 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver...
Vital Therapies Announces Pricing of Public Offering of Common Stock
22. Oktober 2015 23:59 ET
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver...
Vital Therapies Announces Proposed Public Offering of Common Stock
22. Oktober 2015 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver...
Vital Therapies Provides Corporate Update and Announces Date of Third Quarter 2015 Financial Results
16. Oktober 2015 08:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 16, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...